More evidence suggests that PSA testing leads to “overdiagnosis” of cancerBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7560.166-a (Published 20 July 2006) Cite this as: BMJ 2006;333:166
- Roger Dobson
More research suggesting that the widespread use of the prostate specific antigen (PSA) test leads to the overdiagnosis of prostate cancer was published last week (British Journal of Cancer 2006 Jul 11, doi:10.1038/sj.bjc.6603246).
“This study shows that a substantial minority of the observed excess of cases in recent years is likely to be due to PSA testing. A majority of the observed excess in the tested group is estimated to be overdiagnosis,” say the authors from Cambridge University and the Wolfson Institute of Preventive Medicine.
Overdiagnosis was defined by the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial